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Abstract
Background: Cold blood cardioplegia is widely used as a method of myocardial protection in pediatric cardiac surgery. Operative
interruption to administer cardioplegia and need for repeated administration and occasional direct coronary ostial cannulation are
considered a drawbacks of this technique. Custodiol, a crystalloid solution, has been used in children as an alternative cardioplegia
solution with the potential advantage of single dose administration with equivalent myocardial protection. We sought to compare
the outcomes of cold blood cardioplegia versus Custodiol cardioplegia in pediatric cardiac surgery.
Methods: A retrospective cohort study was performed between November 1st, 2013 and June 30th, 2014. All children who un-
derwent heart surgery at two institutions with the use of cardiopulmonary bypass and cardioplegia were included. Patients were
identified from a prospective database and additional data were collected from operative report and electronic and paper charts.
Continuous data were represented as median and interquartile range, and tested withWilcoxon rank-sum test. Categorical data were
represented as proportions, and tested with Pearson test. A composite endpoint of all cause death, Low Cardiac Output Syndrome
(LCOS), Acute Kidney Injury (AKI), and significant arrhythmia was analyzed with a multiple logistic regression model adjusted for
complexity using the Risk Adjustment of Congenital Heart Surgery -1 (RACHS-1) categories. A p-value of less than 0.05 was
considered to be significant.
Results: Blood cardioplegia was administered in 88 (57.1%) patients, and Custodiol cardioplegia was administered in 66 (42.9%)
patients according to surgeon's preference. In the risk adjusted comparison of the composite outcome of all-cause death, LCOS,
AKI and significant arrhythmia, Custodiol cardioplegia was found to be an independent predictor of an adverse outcome, OR 3.17
(95% CI 1.41e7.14, P-value ¼ 0.0054).
Conclusions: Custodial cardioplegia is associated with less optimal myocardial protection and higher adverse outcomes compared
to cold blood cardioplegia in children undergoing cardiac surgery. A randomized comparison is warranted.
Copyright © 2016, The Egyptian Society of Cardio-thoracic Surgery. Publishing services by Elsevier B.V. This is an open access
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Mechanical Ventilation; RACHS-1, Risk Adjustment in Congenital Cardiac Surgery e Version 1.
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39E.A. Qulisy et al. / Journal of the Egyptian Society of Cardio-Thoracic Surgery 24 (2016) 38e42Ultra-mini abstract: In a retrospective multicenter study, 88 children received blood cardioplegia, and 66 received Custodiol
cardioplegia. In a risk adjusted comparison of the composite outcome of all-cause death, morbidity and significant arrhythmia,
Custodiol cardioplegia was found to be an independent predictor of an adverse outcome, OR 3.17 (95% CI 1.41e7.14,
P-value ¼ 0.0054).
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Cardioplegia, a solution used to stop the heart, is an essential tool for cardiac surgery. In conjunction with car-
diopulmonary bypass it provides a motionless bloodless protected heart for the surgeon to repair any intra-cardiac or
extra-cardiac defect. This is achieved by arresting the heart and minimizing myocardial metabolism during the
ischemic time. After placing the patient on cardiopulmonary bypass, the cardioplegia solution is infused in the
clamped proximal ascending aorta exclusively supplying the coronary arteries perfusing the myocardium. The ideal
cardioplegia solution should provide excellent myocardial protection, cause minimal systemic electrolyte imbalance,
and be effective for prolonged periods of time to minimize repeated administration. In a survey of congenital heart
surgeons, Kotani et al. identified that there is no agreement between surgeons about the ideal cardioplegia solution [1].
The main types of cardioplegia used are blood based cardioplegia and crystalloid based cardioplegia. Recently, there
has been growing interest in the use of a more simplified solution that offers simplified perfusion technique, prolonged
ischemic tolerance and minimized disruption during surgery. The Histidine-Tryptophan-Ketoglutarate solution,
known as HTK Custodiol (Essential Pharmaceuticals, LLC, Newton, PA, and MACURE PHARMA ApS, Copen-
hagen, Denmark) has emerged as an option [2]. The goal of this study was to compare the safety and efficacy of
Custodiol cardioplegia versus blood cardioplegia.
2. Methods
A multi-centered, retrospective review was conducted at two institutions. The participating institutions were Abdullah Bakhsh
Children's Heart Center, King Abdulaziz University, Jeddah, Saudi Arabia and the division of cardiovascular surgery, King Faisal
Specialist Hospital, Jeddah, Saudi Arabia. The study protocol was approved by the research ethics boards at both institutions. All
children (1 daye18 years of age) who underwent congenital heart surgery with the use of cardiopulmonary bypass and cardioplegia
between November 2013 and June 2014 at one of the two participating institutions were included. Patients were divided into two
groups on the basis of the cardioplegia solution used. In the Blood group, cardioplegia was given in the standard ratio of (4:1) four
parts of blood from the cardiopulmonary bypass circuit, and one part potassium-rich crystalloid (K ¼ 60 ml eq/L) named Plegisol
(Hospira, Inc, Lake Forest, IL). The initial dosewas 30 ml/kg body weight, and subsequent doses were 20ml/kg given every 20 min.
Temperature was reduced to 10e15 C, while maintaining a perfusion pressure of 100e125mmHg. In contrast, the Custodiol group
was given Custodiol solution at 4e8 C perfused for 5 min. The dose was 40 ml/kg body weight, with a minimum of 5 min of
perfusion time.
All available electronic and paper patient charts as well as the perfusion record, the anesthetic chart, the intensive care record
and the operative reports were examined. All cause death was defined as death during the index admission from any cause and
regardless of length of stay. Low Cardiac Output Syndrome (LCOS) was defined as the use of more than 0.7 mic/kg/min of
Milrinone and/or more than 0.05 mic/kg/min of Epinephrine for more than 5 days. The length of Mechanical Ventilation (MV) was
defined as time of mechanical ventilation using endotracheal intubation in hours, re-intubation episodes and subsequent ventilation
time was added. Acute Kidney Injury (AKI) was defined as postoperative increase in serum creatinine of more than double the
preoperative baseline at any point up to hospital discharge. Significant arrhythmia was defined as any sustained cardiac arrhythmia
requiring pharmacologic intervention or cooling of body temperature. Length of ICU stay in days and length hospital stay in days
were also reported.
2.1. Statistical analysis
Variable distribution was checked for normality. Continuous data were represented as median and interquartile range, while
categorical data were represented as frequencies and proportions. Differences between two groups were analyzed using non
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adjusted comparison between the two groups a composite outcome was created. This composite outcome was defined as any of the
following; death from any cause during the index admission, LCOS, AKI, mechanical ventilation longer that 48 h, or significant
arrhythmia. A multiple logistic regression model including age, weight, Risk Adjustment in Congenital Heart Surgery (RACHS-1)
categories2, and type of cardioplegia was used. A P-value of less than 0.05 was considered to be significant.
3. Results
A total of 154 patients were included in the analysis, this excludes two patients who met inclusion criteria but had
significant missing variables. Blood cardioplegia was administered in 88 (57.1%) patients, and Custodiol cardioplegia
was administered in 66 (42.9%) patients. Demographics and perioperative characteristics of the Blood and Custodiol
groups are summarized in Table 1. The RACHS-1 categories are also reported. The unadjusted outcomes and test of
significant differences are reported in Table 2. Patients receiving Custodiol vs. Blood had longer MV times, median 47
vs. 72 min (p-value¼ 0.005). A trend was also noted for more prevalent LCOS in the Custodiol vs. Blood groups, 33%
vs. 23% (p-value¼ 0.14). The composite outcomewas significantly more prevalent in the Custodiol vs. Blood groups,
68% vs. 49% (p-value ¼ 0.021). In the risk adjusted comparison using multivariable logistic regression with the
composite outcome of all-cause death, the cause of death was not necessarily related to cardioplegia but mostly to
complex surgery& low cardiac output state, LCOS, AKI and significant arrhythmia and adjusting for body weight and
RACHS-1 risk category, Custodiol cardioplegia was found to be an independent predictor of an adverse outcome, OR
3.17 (95% CI 1.41e7.14, P-value ¼ 0.0054), Table 3.
4. Discussion
Myocardial protection is crucial during the repair of congenital heart diseases, and plays a key role in achieving
successful results in heart surgery [3,4]. The aim of myocardial protection is to preserve cardiac function, enhance
ideal oxygen delivery, and minimize both metabolic ischemia and myocardial edema, while generating a bloodless
surgical field which facilitates cardiac repair in an arrested relaxed heart. Strategies for myocardial protection vary
among surgeons with insufficient data regarding the optimal cardioplegic solution [1,3,4]. Custodiol cardioplegia has
been used in hundreds of cases worldwide; it has been more recently used in children including neonates. Some
studies in adults have shown that it may be equivalent to conventional blood cardioplegia [5,6]. A survey conducted
among congenital heart surgeons demonstrated that blood-base cardioplegia was used by almost 90% [1]. Custodiol
cardioplegia is believed to be convenient, simple to delivered, and less time consuming [5,7]. On the other hand, blood
cardioplegia must be re-administered every twenty minutes to maintain its protective properties [8,9]. The current
study shows that children including neonates who receive Custodiol cardioplegia for myocardial protection may haveTable 1
Preoperative patients' characteristics.
Blood n ¼ 88 Custodiol n ¼ 66
Male gender 47% (41) 56% (37)
Age days 305.50 (98.25,1264.75) 291.50 (145.25, 757.25)
Weight kg 6.000 (4.250, 12.000) 6.650 (4.925, 9.775)
Preoperative Creatinine mmol/L 28.00 (23.00, 34.50) 26.00 (18.00, 30.00)
RACHS-1 category
Category 1 8% (7) 0% (0)
Category 2 41% (35) 45% (30)
Category 3 35% (30) 33% (22)
Category 4 3% (3) 6% (4)
Category 5/6 10% (9) 5% (3)
Uncategorized 2% (2) 11% (7)
CPB time min 77 (50, 93) 98 (70,136)
Cross clamp time min 49 (32, 69) 65 (48, 91)
Total operative time min 168 (131, 202) 195 (159, 247)
Data are presented as Median and Interquartile Range (IQR) and Percentile (Frequencies).
CPB: Cardiopulmonary Bypass.
Table 2
Unadjusted outcomes.
Outcome Blood n ¼ 88 Custodiol n ¼ 66 Test P-value
All cause death 5% (4) 9% (6) 0.24a
LCOS 23% (20) 33% (22) 0.14a
MV time hours 47 (12,96) 72 (24,168) 0.005b*
Acute kidney injury (AKI) 15% (13) 26% (17) 0.086a
Significant arrhythmia 17% (15) 20% (13) 0.67a
ICU length of stay days 5 (3, 8) 7 (3, 10) 0.24b
Hospital length of stay days 17 (10, 27) 18 (11, 28) 0.6b
Composite: Death, LCOS, AKI, prolonged MV, or significant arrhythmia 49% (43) 68% (43) 0.021a*
LCOS: Low Cardiac Output Syndrome, MV: Mechanical ventilation, ICU: Intensive Care Unit, Prolonged MV: MV longer than 48 h. *: P-
value < 0.05.
a Categorical variables were tested with Pearson Chi square test.
b Continuous variables were tested with the non-parametric Wilcoxon rank sum test.
Table 3
Risk adjusted composite outcome logistic regression model.
Variable b Odds ratio (CI) P-value
Cardioplegia: Custodiol vs. Blood 1.15 3.17 (1.41e7.15) 0.0054
RACHS-1 0.045
Category 1 vs. category 2 1.42 4.12 (0.79e21.41)
Category 3 vs. category 2 1.22 3.39 (1.51e7.63)
Category 4 vs. category 2 9.87 >100
Category 5/6 vs. category 2 10.12 >100
RACHS-1: Risk Adjustment in Congenital Heart Surgery e version 1. CI: 95% confidence interval.
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cause death was higher with Custodiol versus Blood cardioplegia, this did not reach statistical significance in this
study.
In adults, a meta-analysis of fourteen studies compared Custodiol versus conventional blood cardioplegia for
myocardial protection. Eight out of the fourteen studies reported the incidence of ventricular arrhythmias during
reperfusion. Overall, results showed that there was an increased incidence of ventricular fibrillation with Custodiol
that did not reach statistical significance. However, a prospective randomized study in patient having mitral valve
surgery reported a significantly more spontaneous ventricular fibrillation in the operating room and postoperative
arrhythmias were higher with Custodiol [3]. Gaudino et al., reported lower right ventricular ejection fraction, lower
cardiac indices and longer duration on inotropes in patients who had Custodiol cardioplegia with poor preoperative
right ventricular function [10]. Finally, a randomized clinical trial comparing single-dose Custodiol versus multiple
dose blood cardioplegia in 80 consecutive patients operated on for mitral repair, using Troponin-T and Creatinine
Kinase MB as a markers of myocardial ischemia concluded that Custodiol provides insufficient protection [10,11].
On the other hand, in two studies conducted among adults who underwent repair of the thoracic aorta demonstrated
that the incidence of inotropic use and LCOS was similar for patient receiving Custodiol and blood cardioplegia
[9,12]. Some studies recommend the use of custodial in adult cardiac surgery. Custodiol seems to offer myocardial
protection that is equivalent to that of conventional blood cardioplegia. Moreover, a single dose cardioplegia strategy
for myocardial protection has significant advantages for the performance of heart surgery particularly complex cardiac
operations [13].
The present study is limited by the retrospective nature of the analysis and the small number of patients. The non-
randomized nature of such study also limits its validity; however, we attempted to reduce this problem by adjusting for
the complexity of cases by including RACHS-1 as a variable in the adjusted analysis. A prospective randomized trial
may be warranted to confirm or dismiss our findings.
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In children undergoing cardiac surgery, Custodiol cardioplegia may be associated with less effective myocardial
protection and higher adverse outcomes compared to blood cardioplegia.
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